Posted in | News | Nanomaterials

Irilliant Announces New Patent for Controlled Synthesis of Nanomaterials

Irilliant, Inc., a developer of high-throughput manufacturing processes for nanomaterials, has further enhanced and protected its CAFS (Chemical Aerosol-Flow Synthesis) process with a soon-to-be-issued U.S. patent.

The patent, "Controlled synthesis of nanoparticles using continuous liquid-flow aerosol method," will include claims for large-scale production of high-quality nanoparticles from aerosol. Earlier patented processes were not suitable for large-scale production, nor did they result in products of equally high quality.

In Irilliant's CAFS process, liquid containing the precursors for the synthesis flows continuously through a sprayer, which in turn generates micron-sized droplets. These droplets serve as microreactors, and facilitate the creation of narrow-size distributed nanoparticles. Spraying large amounts of liquid in the reactor, facilitates manufacture of high-quality, surface-stabilized nanoparticles in large quantities. Ultrasonic or large scale industrial sprayers can be used to further enhance throughput. This configuration permits production of a higher quality product with a greater yield compared to previous methods.

Nanomaterials are used in a variety of emerging technologies including next generation photovoltaics, electronic displays, and lighting. "To sustain the explosive growth in these arenas, reliable, high volume production of nanomaterials at the proper pricing points will be needed," said Stephanos Papademetriou, Irilliant's President and CEO. "This addition to our IP portfolio gives us a tremendous competitive advantage. It also moves us closer to our goal of becoming a global leader in the production of a diverse array of quality nanomaterials at price points that are orders of magnitude lower than any other method of nanomaterial synthesis."

Source: Irilliant, Inc.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.